Full identifier: http://purl.org/np/RA2-dISS3g4AXlPLECdvCYWNM2vSt8CBR6UHbVdQrBTHw#assertion
| Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
|---|---|---|---|---|---|---|
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Elif Ozkan
|
2022-10-13T11:44:43.063Z
|
|||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
2022-10-13T11:44:43.063138
|
Elif Ozkan
|
2022-10-13T11:44:43.063Z
|
||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The largest and most consistent cardiovascular outcome benefit has been a reduction in stroke. There are no controlled trials demonstrating risk reduction with nebivolmolol tablets. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients.
|
Elif Ozkan
|
2022-10-13T11:44:43.063Z
|